ProCE Banner Activity

Treatment-Resistant Bipolar Disorders

Slideset Download
This presentation on treatment-resistant bipolar disorders reviews treatments effective in resistant mania; comorbidities in bipolar disorder; innovative treatment options; and efficacy of various treatments in bipolar disorder.

Released: March 22, 2022

Expiration: March 21, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Roger McIntyre

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Roger McIntyre, MD, FRCPC, has disclosed that he has received speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Eisai, Intra-Cellular, Abbvie. Dr. Roger McIntyre is CEO of Braxia Scientific Corp.